Cargando…
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion
Autores principales: | Offer, Katharine, McGuire, Michael T., Song, Kunchang, Goldfischer, Michael J., Davare, Monika A., Corless, Christopher L., Beadling, Carol, Neff, Tanaya, Cox, Michael C., Govinda Raju, Sandya, Blackman, Samuel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581647/ https://www.ncbi.nlm.nih.gov/pubmed/37410972 http://dx.doi.org/10.1200/PO.23.00065 |
Ejemplares similares
-
Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib
por: Tkacik, Emre, et al.
Publicado: (2023) -
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
por: Rasco, Drew W., et al.
Publicado: (2023) -
LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
por: Kilburn, Lindsay, et al.
Publicado: (2023) -
Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences
por: Wood, Matthew D., et al.
Publicado: (2023) -
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
por: Subbiah, Vivek, et al.
Publicado: (2014)